Developer docs
API playgroundTry for free, no card

Search company profiles

Kitazato

Full company profile

uuid00037yn

Namestring
Kitazato
Legal namestring
Kitazato Corporation
Company typeenum
Private
Founded yearint
1998
Descriptiontext

Kitazato Corporation is a Japanese medical-device company founded in 1998 and headquartered in Fuji, Shizuoka, that develops, manufactures, and distributes consumables and instruments for assisted reproductive technology (ART). Its core technology is vitrification — most notably the proprietary Cryotop® Method (launched 2000), an open-system, minimum-volume device for oocyte and embryo cryopreservation that became the field standard. The portfolio spans the full IVF lifecycle across six categories: vitrification devices and media (Cryotop®, Ultra-Fast Vitri, HPC-based vitrification/thawing media), micromanipulation tools (ICSI injection, holding, biopsy, and PZD pipettes), culture media and oils (Hypure® Oils with endotoxin levels below 0.1 EU/ml, Gamete Buffer, Fertilization Medium, Flushing Buffer, sequential and single-step culture media), andrology media (SepaSperm®, PVP, Sperm Freeze), oocyte retrieval needles (single- and double-lumen, 16G–21G), and catheters (EC-PRO Straight ET, Precurved ET, RYDEN™ echogenic ET, IUI, and the Towako® Method for transmyometrial transfer). The product set exceeds 550 SKUs.

Revenue is generated primarily through direct sales of medical devices and consumables to IVF clinics, fertility centers, and andrology laboratories, supplemented by licensing/royalty components for the Cryotop® Method. No public pricing is disclosed; transactions are routed through authorized distributors. Kitazato serves more than 3,000 clinics across 80+ countries via a hybrid go-to-market combining channel partners (Biomedical Supply/Dibimed in EMEA, Kitazato Dibimed USA and UK in North America/UK, plus regional distributors in APAC, LATAM, Africa, and MENA) and enterprise field sales with product specialists who deliver hands-on workshops and training. The company holds MDR CE (notified body 2797) and FDA clearances on key products, and trades on the Tokyo Stock Exchange under ticker 368A.

Short descriptiontext

Kitazato Corporation is a Japanese medical-device company that manufactures and distributes consumables, instruments, and media for the full IVF lifecycle. Founded in 1998 and publicly traded on the Tokyo Stock Exchange (368A), it serves 3,000+ fertility clinics in 80+ countries via its proprietary Cryotop® vitrification method and a 550+ SKU portfolio.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersFuji, Japan
HQ citystring
Fuji
HQ countrystring
Japan
HQ regionstring
Asia
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
IVF medical devices, assisted reproduction consumables, vitrification media, embryo culture media, micromanipulation pipettes
Industry1 code
1Sample Preparation, Storage & Cryogenics (Freezers, Cryovials, Cryostats)
CodeHLAGAIAJPrimaryYes
NAICS code1 code
  • Surgical Appliance and Supplies Manufacturing339113
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Assisted Reproductive Technology (IVF) Medical Devices
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Medical Device Sales - IVF Products
TypeHardware Sales
Description

Kitazato generates revenue through the sale of medical devices and consumables for assisted reproductive technology procedures. Products include vitrification media, oocyte retrieval needles, embryo transfer catheters, micro tools (ICSI pipettes, holding pipettes, biopsy pipettes), culture media, and oils. The company offers over 550 product references covering the entire IVF lifecycle.

kitazato-ivf.com
2Vitrification Method Licensing
TypeLicensing Royalties
Description

The Cryotop® Method, Kitazato's proprietary vitrification approach, is distributed globally and may include licensing components for the methodology and associated protocols used by fertility clinics worldwide.

kitazato-ivf.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Kitazato researches, develops, and manufactures medical devices and consumables for assisted reproductive technology (ART), including vitrification systems, IVF culture media, micromanipulation pipettes, oocyte retrieval needles, and embryo transfer catheters. The company's flagship Cryotop® Method, launched in 2000, popularized oocyte and embryo vitrification globally, and the portfolio of 550+ product references covers the entire IVF lifecycle from oocyte retrieval through embryo transfer. Products are sold to fertility clinics, IVF centers, and andrology laboratories in over 80 countries through authorized distributors and direct sales representatives.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Endotoxin levels kept below 0.1 EU/ml - the lowest among all commercially available culture oils
+4 more records
Product overview1 text field

Kitazato is a Japanese medical device corporation that offers a comprehensive portfolio of over 550 products covering the entire IVF lifecycle. The product suite is organized into six main categories: Vitrification (Cryotop® Method, Vitrification/Thawing Media, Ultra-Fast Media, Ovarian Tissue devices), Micro Tools (ICSI Injection, Holding, Biopsy, and PZD Pipettes), Media and Oils (Hypure® Oils, IVF Media including Gamete Buffer, Hyaluronidase, Fertilization Medium, Flushing Buffer, Culture Media, Andrology Media including SepaSperm®, PVP, Sperm Freeze), Needles (Single and Double Lumen Oocyte Retrieval Needles, Special Procedure Needles), and Catheters (Embryo Transfer catheters including EC-PRO Straight, Precurved, and RYDEN ET; IUI Catheters; Towako® Method). The flagship Cryotop® Method revolutionized vitrification in assisted reproduction, and the portfolio supports every step from oocyte retrieval through embryo transfer, with products co-developed with major Japanese clinics and manufactured to strict quality standards with MDR CE and FDA compliance.

Product and service4 records
1Cryotop® Open Vitrification System
CategoryVitrification devices
Description

Minimum-volume open vitrification device for oocyte and embryo cryopreservation. Achieves the highest survival rates through direct contact with liquid nitrogen during vitrification and storage. Used by fertility clinics and IVF centers worldwide.

2Vitrification and Thawing Media
CategoryVitrification media
Description

Cryopreservation media containing DMSO and EG as permeable cryoprotectants and trehalose as non-permeable cryoprotectant, designed for use with the Cryotop® Method. Uses HPC instead of HSA to eliminate pathogen transmission risk. For fertility clinics performing vitrification and warming.

3Ultra-Fast Vitri
CategoryVitrification media
Description

MDR CE-marked ultra-fast vitrification medium enabling a 2-minute protocol with only 2 steps (1 minute in ES and 1 minute in VS). Minimizes osmotic and chemical stress on oocytes while maximizing lab efficiency. For IVF labs seeking high-throughput vitrification workflows.

4Cryotissue® Ovarian Tissue Vitrification System
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Biomedical Supply S.L., operating as Dibimed, serves as the Official Representative of Kitazato for website management, data processing, and European market distribution. Located in Valencia, Spain, Dibimed manages Kitazato's digital presence, customer communications, and EMEA distribution network including EU, UK, and other European markets.

2Kitazato Dibimed USA
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Dedicated US distribution operation providing Kitazato products to American fertility clinics. Handles US-specific regulatory requirements (FDA approvals) and provides localized sales and support services.

kitazato-ivf.com
3Kitazato Dibimed UK
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

UK-specific distribution entity for Kitazato products, providing sales support and distribution services for the British market.

kitazato-ivf.com
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Kitazato maintains authorized distributors in over 80 countries including E.g., EISENBERG BROS. LTD (Israel), Vitagen (Argentina), Gytech (Australia), Fertitech Canada, Shivani Scientific (India), PT. Sonna Medika Jaya (Indonesia), IDS Medical Systems (Singapore), and many others covering major fertility markets worldwide.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

Part of CooperCompanies, one of the largest global suppliers of IVF and reproductive health products (including Wallace catheters and ORIGIO media). Directly competes with Kitazato across needles, catheters, and culture media in the same fertility clinic channel.

TypeDirect peer
Description

FUJIFILM-owned manufacturer of cell culture media and ART products including vitrification media and IVF microtools. Directly comparable to Kitazato as a Japanese/Asia-based competitor offering overlapping product categories to IVF clinics.

TypeDirect peer
Description

Australian-based ART equipment and consumables company with products spanning culture media, microtools, and lab devices. A direct peer with comparable product mix targeting IVF labs, though smaller in scale than Kitazato.

TypeDirect peer
Description

German manufacturer specializing in ART culture media and microtools. Comparable product portfolio to Kitazato in IVF media and pipettes, with overlapping distribution in European fertility clinics.

TypeDirect peer
Description

Swedish-listed global leader in IVF media, consumables, and time-lapse systems (EmbryoScope). Directly competes with Kitazato across culture media and vitrification, serving the same fertility clinic customer base worldwide.

TypeBroad incumbent
Description

German multinational with significant life science tools and fertility/ART offerings (including Genea Biomedx investment and Gonal-f). Competes with Kitazato in the broader ART ecosystem through culture media, devices, and pharmaceuticals.

TypeDirect peer
Description

Germany-based manufacturer of IVF media, micropipettes, and consumables. Directly comparable to Kitazato's media and microtools portfolio, serving European fertility clinics with overlapping ART consumables.

TypeBroad incumbent
Description

US-based diversified medical device manufacturer with a reproductive health division offering needles and ART procedure devices. Wider portfolio than Kitazato, but directly comparable on oocyte retrieval needles and catheters for IVF procedures.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Kitazato

Assisted Reproductive Technology (IVF) Medical Deviceskitazato-ivf.com

Kitazato Corporation is a Japanese medical-device company that manufactures and distributes consumables, instruments, and media for the full IVF lifecycle. Founded in 1998 and publicly traded on the Tokyo Stock Exchange (368A), it serves 3,000+ fertility clinics in 80+ countries via its proprietary Cryotop® vitrification method and a 550+ SKU portfolio.

What Kitazato does

Kitazato Corporation is a Japanese medical-device company founded in 1998 and headquartered in Fuji, Shizuoka, that develops, manufactures, and distributes consumables and instruments for assisted reproductive technology (ART). Its core technology is vitrification — most notably the proprietary Cryotop® Method (launched 2000), an open-system, minimum-volume device for oocyte and embryo cryopreservation that became the field standard. The portfolio spans the full IVF lifecycle across six categories: vitrification devices and media (Cryotop®, Ultra-Fast Vitri, HPC-based vitrification/thawing media), micromanipulation tools (ICSI injection, holding, biopsy, and PZD pipettes), culture media and oils (Hypure® Oils with endotoxin levels below 0.1 EU/ml, Gamete Buffer, Fertilization Medium, Flushing Buffer, sequential and single-step culture media), andrology media (SepaSperm®, PVP, Sperm Freeze), oocyte retrieval needles (single- and double-lumen, 16G–21G), and catheters (EC-PRO Straight ET, Precurved ET, RYDEN™ echogenic ET, IUI, and the Towako® Method for transmyometrial transfer). The product set exceeds 550 SKUs.

Revenue is generated primarily through direct sales of medical devices and consumables to IVF clinics, fertility centers, and andrology laboratories, supplemented by licensing/royalty components for the Cryotop® Method. No public pricing is disclosed; transactions are routed through authorized distributors. Kitazato serves more than 3,000 clinics across 80+ countries via a hybrid go-to-market combining channel partners (Biomedical Supply/Dibimed in EMEA, Kitazato Dibimed USA and UK in North America/UK, plus regional distributors in APAC, LATAM, Africa, and MENA) and enterprise field sales with product specialists who deliver hands-on workshops and training. The company holds MDR CE (notified body 2797) and FDA clearances on key products, and trades on the Tokyo Stock Exchange under ticker 368A.

Kitazato firmographics

Firmographics
Name
Kitazato
Legal name
Kitazato Corporation
Website
https://kitazato-ivf.com
Company type
Private
Founded year
1998
Operating status
Operating
Headcount range
251–500 employees
Short description
Kitazato Corporation is a Japanese medical-device company that manufactures and distributes consumables, instruments, and media for the full IVF lifecycle. Founded in 1998 and publicly traded on the Tokyo Stock Exchange (368A), it serves 3,000+ fertility clinics in 80+ countries via its proprietary Cryotop® vitrification method and a 550+ SKU portfolio.
Ownership category
akta.pro rank

Kitazato industry classification

Industry
Product category
Assisted Reproductive Technology (IVF) Medical Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro primary industry
Sample Preparation, Storage & Cryogenics (Freezers, Cryovials, Cryostats) (HLAGAIAJ)

Keywords

  • IVF medical devices
  • Assisted reproduction consumables
  • Vitrification media
  • Embryo culture media
  • Micromanipulation pipettes

Where Kitazato is headquartered

Location

Headquarters

HQ city
Fuji
HQ country
Japan
HQ region
Asia

Offices4 records

Markets served

Kitazato business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Medical Device Sales - IVF Products: Kitazato generates revenue through the sale of medical devices and consumables for assisted reproductive technology procedures. Products include vitrification media, oocyte retrieval needles, embryo transfer catheters, micro tools (ICSI pipettes, holding pipettes, biopsy pipettes), culture media, and oils. The company offers over 550 product references covering the entire IVF lifecycle.
  2. Vitrification Method Licensing: The Cryotop® Method, Kitazato's proprietary vitrification approach, is distributed globally and may include licensing components for the methodology and associated protocols used by fertility clinics worldwide.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Kitazato product offering

Product offering

Core offering

Kitazato researches, develops, and manufactures medical devices and consumables for assisted reproductive technology (ART), including vitrification systems, IVF culture media, micromanipulation pipettes, oocyte retrieval needles, and embryo transfer catheters. The company's flagship Cryotop® Method, launched in 2000, popularized oocyte and embryo vitrification globally, and the portfolio of 550+ product references covers the entire IVF lifecycle from oocyte retrieval through embryo transfer. Products are sold to fertility clinics, IVF centers, and andrology laboratories in over 80 countries through authorized distributors and direct sales representatives.

Product overview

Kitazato is a Japanese medical device corporation that offers a comprehensive portfolio of over 550 products covering the entire IVF lifecycle. The product suite is organized into six main categories: Vitrification (Cryotop® Method, Vitrification/Thawing Media, Ultra-Fast Media, Ovarian Tissue devices), Micro Tools (ICSI Injection, Holding, Biopsy, and PZD Pipettes), Media and Oils (Hypure® Oils, IVF Media including Gamete Buffer, Hyaluronidase, Fertilization Medium, Flushing Buffer, Culture Media, Andrology Media including SepaSperm®, PVP, Sperm Freeze), Needles (Single and Double Lumen Oocyte Retrieval Needles, Special Procedure Needles), and Catheters (Embryo Transfer catheters including EC-PRO Straight, Precurved, and RYDEN ET; IUI Catheters; Towako® Method). The flagship Cryotop® Method revolutionized vitrification in assisted reproduction, and the portfolio supports every step from oocyte retrieval through embryo transfer, with products co-developed with major Japanese clinics and manufactured to strict quality standards with MDR CE and FDA compliance.

Differentiator

Problem solved

Functional benefit

Products and services

  • Cryotop® Open Vitrification System Minimum-volume open vitrification device for oocyte and embryo cryopreservation. Achieves the highest survival rates through direct contact with liquid nitrogen during vitrification and storage. Used by fertility clinics and IVF centers worldwide.
  • Vitrification and Thawing Media Cryopreservation media containing DMSO and EG as permeable cryoprotectants and trehalose as non-permeable cryoprotectant, designed for use with the Cryotop® Method. Uses HPC instead of HSA to eliminate pathogen transmission risk. For fertility clinics performing vitrification and warming.
  • Ultra-Fast Vitri MDR CE-marked ultra-fast vitrification medium enabling a 2-minute protocol with only 2 steps (1 minute in ES and 1 minute in VS). Minimizes osmotic and chemical stress on oocytes while maximizing lab efficiency. For IVF labs seeking high-throughput vitrification workflows.
  • Cryotissue® Ovarian Tissue Vitrification System

Quantifiable outcome

  • Endotoxin levels kept below 0.1 EU/ml - the lowest among all commercially available culture oils
  • +4 more outcomes

Companies that use Kitazato

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Kitazato technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature8 records

Kitazato partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • Biomedical Supply S.L. (Dibimed)coreChannel Partner/ Reseller/ DistributorBiomedical Supply S.L., operating as Dibimed, serves as the Official Representative of Kitazato for website management, data processing, and European market distribution. Located in Valencia, Spain, Dibimed manages Kitazato's digital presence, customer communications, and EMEA distribution network including EU, UK, and other European markets.
  • Kitazato Dibimed USAcoreChannel Partner/ Reseller/ DistributorDedicated US distribution operation providing Kitazato products to American fertility clinics. Handles US-specific regulatory requirements (FDA approvals) and provides localized sales and support services.
  • Kitazato Dibimed UKcoreChannel Partner/ Reseller/ DistributorUK-specific distribution entity for Kitazato products, providing sales support and distribution services for the British market.
  • Global Distributor Network (80+ countries)coreChannel Partner/ Reseller/ DistributorKitazato maintains authorized distributors in over 80 countries including E.g., EISENBERG BROS. LTD (Israel), Vitagen (Argentina), Gytech (Australia), Fertitech Canada, Shivani Scientific (India), PT. Sonna Medika Jaya (Indonesia), IDS Medical Systems (Singapore), and many others covering major fertility markets worldwide.

Scale indicators5 records

Recent moves5 records

Expansion highlights5 records

Kitazato competitors and assessment

Company assessment

Direct peers

  • CooperSurgical: Part of CooperCompanies, one of the largest global suppliers of IVF and reproductive health products (including Wallace catheters and ORIGIO media). Directly competes with Kitazato across needles, catheters, and culture media in the same fertility clinic channel.
  • FUJIFILM Irvine Scientific: FUJIFILM-owned manufacturer of cell culture media and ART products including vitrification media and IVF microtools. Directly comparable to Kitazato as a Japanese/Asia-based competitor offering overlapping product categories to IVF clinics.
  • Genea Biomedx: Australian-based ART equipment and consumables company with products spanning culture media, microtools, and lab devices. A direct peer with comparable product mix targeting IVF labs, though smaller in scale than Kitazato.
  • Gynemed: German manufacturer specializing in ART culture media and microtools. Comparable product portfolio to Kitazato in IVF media and pipettes, with overlapping distribution in European fertility clinics.
  • Vitrolife: Swedish-listed global leader in IVF media, consumables, and time-lapse systems (EmbryoScope). Directly competes with Kitazato across culture media and vitrification, serving the same fertility clinic customer base worldwide.
  • Vitromed: Germany-based manufacturer of IVF media, micropipettes, and consumables. Directly comparable to Kitazato's media and microtools portfolio, serving European fertility clinics with overlapping ART consumables.

Broad incumbents

  • Merck KGaA (Life Science / Fertility): German multinational with significant life science tools and fertility/ART offerings (including Genea Biomedx investment and Gonal-f). Competes with Kitazato in the broader ART ecosystem through culture media, devices, and pharmaceuticals.
  • Cook Medical: US-based diversified medical device manufacturer with a reproductive health division offering needles and ART procedure devices. Wider portfolio than Kitazato, but directly comparable on oocyte retrieval needles and catheters for IVF procedures.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Kitazato social profiles

Digital presence

Kitazato compliance and trust

Trust signal

Compliance3 records

Kitazato financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Kitazato leadership team

Management profile

Number of profiles

Profiles1 record

Kitazato funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Kitazato M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kitazato

What does Kitazato do?

Kitazato researches, develops, and manufactures medical devices and consumables for assisted reproductive technology (ART), including vitrification systems, IVF culture media, micromanipulation pipettes, oocyte retrieval needles, and embryo transfer catheters. The company's flagship Cryotop® Method, launched in 2000, popularized oocyte and embryo vitrification globally, and the portfolio of 550+ product references covers the entire IVF lifecycle from oocyte retrieval through embryo transfer. Products are sold to fertility clinics, IVF centers, and andrology laboratories in over 80 countries through authorized distributors and direct sales representatives.

Is Kitazato a public or private company?

Kitazato is a private company. It is classified as public and is currently operating.

When was Kitazato founded?

Kitazato was founded in 1998. It employs 251 to 500 people.

Where is Kitazato based?

Kitazato is headquartered in Fuji, Japan, in the Asia region.

How does Kitazato make money?

Two revenue lines are on record. Medical Device Sales - IVF Products are the primary driver. The others are vitrification Method Licensing.

Who are Kitazato's main competitors?

Direct peers on record are CooperSurgical, FUJIFILM Irvine Scientific, Genea Biomedx, Gynemed, Vitrolife and Vitromed. Broad incumbents are Merck KGaA (Life Science / Fertility) and Cook Medical.

Does Kitazato have an API?

No public API is recorded for Kitazato.

What industry is Kitazato in?

Kitazato's product category is Assisted Reproductive Technology (IVF) Medical Devices. Its primary akta.pro industry code is HLAGAIAJ, Sample Preparation, Storage & Cryogenics (Freezers, Cryovials, Cryostats). Its NAICS code is 339113 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PrtimesBristol Corporation, addressing the shortage of medical and nursing personnel in Japan.Kitasato Corporation partnered with LPK MOGI ASIA PRIMA in Indonesia to train local youth in Japanese language and nursing skills. The project aims to introduce about 100 nursing assistants to Japanese medical institutions monthly, with a one-year employment guarantee. The company plans to expand similar initiatives in Myanmar, Nepal, and Indonesia.EIN PresswireHanabusa IVF Awarded Best Practice Recognition for Cryopreservation Excellence by Kitazato IVFHanabusa IVF was awarded Best Practice Recognition by Kitazato for exceptional vitrification outcomes at the 2025 ASRM Scientific Congress & Expo in San Antonio, Texas. The recognition validates Hanabusa IVF's outstanding cryopreservation performance using the Kitazato Cryotop Method and confirms its role as the dedicated laboratory for Asian Egg Bank, the world's largest provider of frozen Asian donor eggs. Through this partnership, Hanabusa IVF and Asian Egg Bank have made geographically relevant frozen donor egg options more accessible to clinics and patients worldwide.The WorldfolioKitazato’s Cryotop Method, the future of embryo cryopreservationKitazato Corporation is advancing fertility treatment technology with its Cryotop Method, which significantly increases the survival rate of cryopreserved eggs and embryos. The company aims to reduce the costs of fertility treatments to make them more accessible worldwide. It continues to innovate through research, manufacturing, and global collaborations, particularly focusing on Asia and expanding its international presence.PR NewswireGlobal Intrauterine Insemination (IUI) Devices Markets, 2023-2027: Advancements in Healthcare Facilities & Rising Awareness and Initiatives by Governments to Bolster GrowthResearchAndMarkets.com has published a market research report projecting impressive growth in the global intrauterine insemination (IUI) devices market during 2023-2027, driven by rising infertility rates, technological advancements, and increasing government investments. The report identifies key market drivers including rising awareness among populations, new government regulations such as India's 2020 Assistive Reproductive Technology Regulation Bill, and technological developments in automation and AI for fertility treatment. The competitive landscape includes major players such as Kitazato Corporation, CooperSurgical, Inc., Cook Group Inc., and others, with the United States expected to be a lucrative market.